Cannabis for Crohn’s disease
Crohn’s disease is a chronic inflammatory bowel disease (IBD) that can inflame any part of the gastrointestinal tract, from the mouth to the anus. It produces a familiar and exhausting cluster of symptoms — abdominal pain, diarrhea, fatigue, weight loss, and systemic inflammation — and it can flare unpredictably. Conventional treatment has come a long way, but many patients still struggle with break-through symptoms, side effects, or steroid dependency.
Cannabis is not a cure for Crohn’s disease, and it does not replace disease-modifying drugs like biologics. But a growing body of research, including small randomized trials, suggests that cannabinoids can meaningfully improve Crohn’s-related symptoms and quality of life. The gut is dense with endocannabinoid system (ECS) receptors, which helps explain why THC, CBD, and the minor cannabinoid CBG can modulate pain, motility, inflammation, and appetite.
Below, Leafwell’s medical team walks through what the research says, which cannabinoids and delivery methods are best suited to specific Crohn’s scenarios, how to dose, which drug interactions to watch for, and how to qualify for a medical marijuana card.
How cannabis works for Crohn’s disease
The gastrointestinal tract contains one of the highest densities of endocannabinoid receptors in the body. Both CB1 receptors (which dominate in neurons controlling pain and motility) and CB2 receptors (which are heavily expressed on immune cells in the gut lining) regulate inflammation, visceral pain, and gut motility. When Crohn’s inflames the intestine, the ECS is one of the body’s own braking systems — and plant cannabinoids can amplify that signal.[1]
What THC does for Crohn’s symptoms
THC is a partial agonist at both CB1 and CB2 receptors. In Crohn’s, that activity translates into three practical benefits: it dulls visceral pain, slows the hyper-motility that drives diarrhea and cramping, and relieves nausea while stimulating appetite — a meaningful effect for patients who have lost weight during a flare. In the 2013 Naftali randomized trial, 10 of 11 patients receiving smoked THC-rich cannabis achieved a clinical response versus 4 of 10 on placebo, with significant improvements in appetite and sleep.[2]
What CBD does for Crohn’s symptoms
CBD does not directly activate CB1 or CB2, but it modulates the ECS indirectly and engages several inflammation-related pathways (PPAR-γ, TRPV1, adenosine signalling). In animal models of colitis, CBD reduces colonic damage, neutrophil infiltration, and pro-inflammatory cytokines. Human trials have been mixed: a 2017 Naftali study of CBD-rich oil (no THC) did not show superiority over placebo for Crohn’s, suggesting that THC may be necessary for the symptomatic benefit — while CBD still has a role in reducing anxiety, improving sleep, and potentially supporting gut-barrier integrity.[3]
Why CBG is interesting for IBD
Cannabigerol (CBG) is a minor, non-intoxicating cannabinoid that has performed well in pre-clinical IBD models. In a 2013 study using murine colitis, CBG reduced nitric oxide production, oxidative stress, and inflammatory markers in colonic tissue. Clinical data in humans is still limited, but CBG is increasingly available in full-spectrum oils and is a plausible adjunct to THC and CBD for patients with active inflammation.[4]
Gut-supporting terpenes
Terpenes are the aromatic compounds that give each cultivar its smell and they contribute to the “entourage effect.” Several are particularly relevant for gut inflammation and Crohn’s-related symptoms:
Crohn’s disease is a qualifying condition in many states
See if you qualify →
- Get approved in minutes
- Same-day appointments available
- Money back guarantee
Choosing the right product, ratio, and dose
There is no single “Crohn’s strain.” The right product depends on whether you are managing an active flare, maintaining remission, or specifically trying to recover appetite and weight. Below are three common scenarios and the products that match them best.
1. Active flare — pain, cramping, nausea
Look for a balanced or THC-dominant product (1:1 or 2:1 THC:CBD), delivered as a tincture, softgel, or — for localized lower-GI inflammation — a rectal suppository. Inhaled flower or a vape can provide rapid breakthrough relief when cramps are severe. Beta-caryophyllene-rich cultivars like OG Kush or GSC are worth trying.
2. Maintenance and remission
Shift toward CBD-dominant products (10:1 to 20:1 CBD:THC) for daily use, ideally taken twice daily as a sublingual oil or capsule. A small microdose of THC (1–2.5 mg) at night can support sleep and calm residual gut hypersensitivity without daytime impairment.
3. Appetite and weight recovery
THC-dominant products taken 30–60 minutes before meals can meaningfully improve appetite. Low-dose edibles or softgels (2.5–5 mg THC) avoid smoke and provide a longer appetite window than inhalation.
Delivery methods compared
How to dose
Cannabis response is highly individual, but a reasonable starting protocol for Crohn’s looks like this:
- THC: Start at 2.5 mg once daily (evening). Increase by 2.5 mg every 3–5 days as tolerated. Many patients settle between 5–15 mg per dose, twice daily.
- CBD: Start at 10–25 mg twice daily. Typical therapeutic range is 25–100 mg per dose.
- Combination (balanced): A 1:1 or 2:1 THC:CBD oil at 5 mg of each cannabinoid twice daily is a common, well-tolerated starting point.
- Track it: Keep a simple journal of dose, time, symptoms, and bowel frequency. Adjust one variable at a time.
Can I get a medical marijuana card for Crohn’s disease?
In most U.S. medical-marijuana states, Crohn’s disease or inflammatory bowel disease (IBD) is either explicitly listed as a qualifying condition or is easily covered under an umbrella condition such as chronic pain, severe nausea, or cachexia. The table below summarizes the status in 38 medical-cannabis states and territories.
State rules change frequently. Confirm the current list for your state on Leafwell’s state-by-state guide, or book a medical evaluation and our clinicians will confirm eligibility for you.
Crohn’s disease is a qualifying condition in many states
See if you qualify →
- Get approved in minutes
- Same-day appointments available
- Money back guarantee
What is Crohn’s disease?
Crohn’s disease is one of the two main forms of inflammatory bowel disease (the other is ulcerative colitis). It is characterized by patchy, transmural inflammation that can affect any part of the GI tract, most often the terminal ileum and colon. An estimated 780,000 Americans are living with Crohn’s, and incidence is rising worldwide.[5]
Types of Crohn’s disease
Crohn’s is usually classified by where in the digestive tract inflammation is located:
- Ileocolitis — the most common form; affects the terminal ileum and colon.
- Ileitis — inflammation limited to the ileum.
- Gastroduodenal Crohn’s — affects the stomach and duodenum; often causes nausea, vomiting, and early satiety.
- Jejunoileitis — patchy inflammation of the jejunum; frequently causes malabsorption and weight loss.
- Crohn’s (granulomatous) colitis — inflammation confined to the colon.
Common symptoms
- Persistent diarrhea (sometimes bloody)
- Abdominal pain and cramping, often in the lower right quadrant
- Fatigue
- Weight loss, loss of appetite
- Fever during flares
- Mouth sores, perianal disease (fissures, fistulas)
- Extraintestinal symptoms: joint pain, skin lesions (erythema nodosum), eye inflammation
Common causes and triggers
The exact cause is unknown, but Crohn’s is best understood as an immune-mediated disease driven by a combination of genetic susceptibility, environmental triggers, and an imbalanced gut microbiome. Known risk factors include:
- Family history of IBD
- Smoking (increases risk and severity of Crohn’s specifically)
- Western diet high in ultra-processed foods
- Frequent NSAID use
- Prior gut infections
- Chronic stress, which can precipitate flares even if it does not cause the disease
Conventional treatments
Standard care for Crohn’s aims to induce remission during flares and maintain it long-term. Options include:
- Aminosalicylates (5-ASAs) — mild disease, limited benefit in Crohn’s specifically.
- Corticosteroids (prednisone, budesonide) — short-term flare control; not for maintenance.
- Immunomodulators (azathioprine, 6-mercaptopurine, methotrexate) — steroid-sparing maintenance.
- Biologics — anti-TNF agents (infliximab, adalimumab), anti-integrin (vedolizumab), anti-IL-12/23 (ustekinumab, risankizumab) for moderate-to-severe disease.
- JAK inhibitors (upadacitinib) — newer oral option for moderate-to-severe Crohn’s.
- Surgery — resection of diseased segments; roughly half of patients eventually need surgery.
- Nutrition — exclusive enteral nutrition in children, specific carbohydrate or Mediterranean-style diets as adjuncts.
Medical cannabis is best positioned as an adjunct to these therapies — helping with pain, nausea, sleep, appetite, and quality of life while disease-modifying drugs do the work of controlling inflammation.
